New Vaccine Candidate to Prevent Chikungunya has been Developed, Alleged News

ACCORDING TO THE TIMES OF INDIA 15 AUGUST 2014, NEW VACCINE CANDIDATE TO PREVENT CHIKUNGUNYA HAS REPORTEDLY BEEN DEVELOPED. 
In a breakthrough, Scientists have have developed a new vaccine candidate to provide protection from the mosquito-borne viral illness Chikungunya. The experimental vaccine allegedly elicited neutralising antibodies in all 25 adult volunteers who participated in an early-stage clinical trial conducted by Researchers at the National Institute of Allergy and Infectious Diseases (NIAID). (1)

The Lancet reports on a chikungunya trial
The Lancet gave background to safety and tolerability of chikungunya virus-like particle vaccine in healthy adults; a phase 1 dose-escalation trial.
Chikungunya virus - a mosquito-borne alphavirus - is endemic in Africa, South and Southeast Asia, and has emerged in the Caribbean. No drugs or vaccines are available for treatment or prevention. The aim of the trial was to assess the safety, tolerability and immunogenicity of a new candidate vaccine.,
Methods; VRC 311 was a phase 1, dose-escalation open-label clinical trial of a virus-like particle (VLP) chikungunya virus vaccine VRC-CHKVLP059-00-VP. Participants were assigned to sequential dose level groups [see document.] (2)
The findings were fully documented. The trial is registerd with ClinicalTrials.gov (3) NCT01489358. 
[4]
The interpretation is that the chikungunya VLP vaccine was immunogenic, safe and well-tolerated. The Lancet considered the study they discussed as representing an important step in vaccine development to combat this rapidly emerging pathogen.
The Lancet recommended that further studies should be done in a larger number of participants and in more diverse populations. (2)


(1) New vaccine to prevent chikungunga developed
http://timesofindia.indiatimes.com/home/science/New-vaccine-to-prevent-chikungunya-developed/articleshow/40309932.cms  

(2) Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults; a phase 1 dose-escalation trial
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736%2814%2961185-5.pdf

(3) https://clinicaltrials.gov/

[4] NCT01489358. 
https://clinicaltrials.gov/show/NCT01489358 

Chikungunya virus Infects more than 1 Million in Americas
http://www.voanews.com/content/chikungunya-virus-has-infected-more-than-1-million-in-americas/2570840.html

*Disclaimer; Please note that the information on this Blog Post is not meant to replace the original information imparted from the resources from which the Post is drawn. The information given above is intended to disseminate information of relevance and interest only. Please check sources to verify that information given above was correctly quoted; No responsibility rests on the writer of the blog posts re same